Corticosteroids for the treatment of Duchenne muscular dystrophy

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  Matthews, Emma ^a   Brassington, Ruth ^a   Kuntzer, Thierry ^b   Jichi, Fatima ^c   Manzur, Adnan Y ^d  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEFLAZACORT; PREDNISOLONE; PREDNISONE; GLUCOCORTICOID; PREGNANE DERIVATIVE;

ABNORMAL BEHAVIOR; ACNE; BEHAVIOR CHANGE; BODY EQUILIBRIUM; BODY MASS; BODY WEIGHT DISORDER; BREATHING MUSCLE; CATARACT; CLIMBING; CORTICOSTEROID THERAPY; COUGHING; CUSHINGOID SYNDROME; DEATH; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRACTURE; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HAIR GROWTH; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INCREASED APPETITE; INFECTION; LEG; MOBILIZATION; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SPINE FRACTURE; SYSTEMATIC REVIEW; WALKING; WEIGHT GAIN; WEIGHT LIFTING; DRUG EFFECTS; MALE; META ANALYSIS; MUSCULAR DYSTROPHY, DUCHENNE;

ADRENAL CORTEX HORMONES; GLUCOCORTICOIDS; HUMANS; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; PREDNISOLONE; PREDNISONE; PREGNENEDIONES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WALKING;

EID: 84965047522     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003725.pub4     Document Type: Review

References (154)

1. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle & Nerve 1994;17(4):386-91. [PUBMED: 8170484]
2. Bäckman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders 1995;5(3):233-41. [PUBMED: 7633189]
3. Beenakker EA, Fock JM, Van Tol MJ, Maurits NM, Koopman HM, Brouwer OF, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology 2005;62(1):128-32. [PUBMED: 15642859]
4. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle & Nerve 2000;23(9):1344-7.
5. Brooke MH. A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology 1996;46:A476.
6. Escolar D, McDonald C, Kornberg AJ, Bertorini T, Nevo Y, Lotze T. Randomized, double-blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology 2008; Vol. 70, issue 11 Suppl 1:A109-10, Abstract no: S05.004.
7. Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011;77(5):444-52. [PUBMED: 21753160]
8. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology 1991;48(4):383-8. [PUBMED: 2012511]
9. Hu J, Ye Y, Kong M, Hong S, Cheng L, Wang Q, et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle & Nerve 2015;52(6):1001-7. [PUBMED: 25809413]
10. Karimzadeh P, Ghazavi A. Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology 2012; Vol. 6, issue 1:5-12.
11. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine 1989;320(24):1592-7. [PUBMED: 2657428]
12. Rahman MM, Hannan MM, Mondol BA, Bhoumick NB, Haque A. Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin 2001;27(1):38-42. [PUBMED: 11692899]
13. Todorovic SM. High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Muscle & Nerve. 1998; Vol. 7 Suppl:72.
14. Ahlander AC, Kroksmark AK, Tulinius M. Low-dosage prednisolone in the long-term treatment of Duchenne muscular dystrophy. Neuromuscular Disorders 2003;13(7-8):630.
15. Alman BA, Raza NS, Biggar WD. Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. Journal of Bone and Joint Surgery. American Volume 2004;86-A(3):519-24.
16. Angelini C, Pegoraro E, Cadaldini M. Daily versus alternate-day deflazacort (DFZ) in Duchenne muscular dystrophy. Neurology 1995;45(Suppl 4):A182.
17. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle & Nerve 2007;36(4):424-35.
18. Angelini C, Peterle E. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myologica 2012; Vol. 31, issue 1:9-15.
19. Luz Aviles C, Gutiérrez C, Novoa F, Gil E, Stuardo A. Steroid treatment of Duchenne's muscular dystrophy [Tratamiento esteroidal en distrofia muscular de Duchenne]. Revista Chilena de Pediatra 1982;53(3):187-91.
20. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. American Journal of Physical Medicine and Rehabilitation 2005;84(11):843-50.
21. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics 2001;138(1):45-50.
22. Biggar WD, Politano L, Harris VA, Passamano L, Vajsar J, Alman B, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders 2004;14(8-9):476-82.
23. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders 2006;16(4):249-55.
24. Bonifati DM, Witchel SF, Ermani M, Hoffman EP, Angelini C, Pegoraro E. The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. Journal of Neurology, Neurosurgery, and Psychiatry 2006;77(10):1177-9.
25. Bothwell JE, Gordon KE, Dooley JM, MacSween J, Cummings EA, Salisbury S. Vertebral fractures in boys with Duchenne muscular dystrophy. Clinical Pediatrics 2003;42(4):353-6.
26. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT 3rd, Miller JP, et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Archives of Neurology 1987;44(8):812-7.
27. Campbell C, Jacob P. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurology 2003; Vol. 3, issue 1:7.
28. Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscular Disorders 2002;12(10):917-25.
29. Daftary AS, Crisanti M, Kalra M, Wong B, Amin R. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics 2007;119(2):e320-4.
30. de Groot IJM. The effectiveness of prednisolone treatment (10 days on/10 days off) in the ambulatory phase of Duchenne muscular dystrophy: an open study. Neuromuscular Disorders 2002;12(7-8):737-8.
31. DeSilva S, Drachman DB, Mellits D, Kuncl R. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Archives of Neurology 1987;44(8):818-22.
32. Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1974;2(7894):1409-12.
33. Dubowitz V, Kinali M, Main M, Mercuri E, Muntoni F. Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. European Journal of Paediatric Neurology 2002;6(3):153-9.
34. Dubrovsky AL, De Vito E, Suarez A, Mesa LE, Pessolano F, Sobrino R, et al. Deflazacort treatment and respiratory function in Duchenne muscular dystrophy. Neurology 1999;52 Suppl(2):A544.
35. Fenichel GM, Mendell JR, Moxley RT, Griggs RC, Brooke MH, Miller JP. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Archives of Neurology 1991;48(6):575-9.
36. Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT 3rd, Griggs RC, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41(12):1874-7.
37. Flanigan KM. The muscular dystrophies. Seminars in Neurology 2012;32(3):255-63.
38. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993;43(3 Pt 1):520-7.
39. Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle & Nerve 2013; Vol. 48, issue 1:27-31.
40. Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, et al. CINRG Investigators. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle & Nerve 2013;48(1):55-67.
41. Houde S, Filiatrault M, Fournier A, Dubé J, D'Arcy S, Bérubé D, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatric Neurology 2008;38(3):200-6.
42. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscular Disorders 2002;12(Suppl 1):S169-74.
43. Kinali M, Main M, Eliahoo J, Messina S, Knight RK, Lehovsky J. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. European Journal of Paediatric Neurology 2007;11(3):160-6.
44. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C. Orthopedic outcomes of long-term daily dose corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007;68(19):1607-13.
45. Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, Cripe LH. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatric Cardiology 2005;26(6):768-71. [10.1007/s00246-005-0909-4]
46. Mayhew AG, Cano SJ, Scott E, Eagle M, Bushby K, Manzur A, et al. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Developmental Medicine and Child Neurology 2013; Vol. 55, issue 11:1046-52.
47. Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PloS One 2013; Vol. 8, issue 1:e52512. [DOI: 10.1371/journal.pone.0052512]
48. McAdam LC, Mayo AL, Alman BA, Biggar WD. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. Acta Myologica 2012; Vol. 31, issue 1:16-20.
49. Merlini L, Cicognani A, Malaspina E, Gennari M, Gnudi S, Talim B, et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle & Nerve 2003;27(2):222-7.
50. Mesa LE, Dubrovsky AL, Corderi J, Marco P, Flores D. Steroids in Duchenne muscular dystrophy - deflazacort trial. Neuromuscular Disorders 1991;1(4):261-6.
51. Pandya S, Myers G, Moxley RT. Effect of daily prednisone on independent ambulation in patients with Duchenne dystrophy treated for up to 15 years. Neuromuscular Disorders 2001;11(6-7):630.
52. Parreira SL, Resende MB, Della Corte Peduto M, Marie SK, Carvalho MS, Reed UC. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arquivos de Neuro-Psiquiatria 2007;65(2A):245-50.
53. Pradhan S, Ghosh D, Srivastava NK, Kumar A, Mittal B, Pandey CM, et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. Journal of Neurology 2006;253(10):1309-16. [DOI 10.1007/s00415-006-0212-1]
54. Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain & Development 1995;17 Suppl:39-43.
55. Resende MBD, Reed UC, Espindola AA, Ferreira LG, Carvalho MS, Diament A, et al. Deflazacort in Duchenne muscular dystrophy: preliminary results in a Brazilian series. Neuromuscular Disorders 2001;11:630.
56. Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. NorthStar Clinical Network. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery & Psychiatry 2013;84(6):698-705.
57. Sansome A, Royston P, Dubowitz V. Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule. Neuromuscular Disorders 1993;3(5-6):567-9.
58. Schara U, Mortier J, Mortier W. Long-term steroid therapy in Duchenne muscular dystrophy-positive results versus side effects. Journal of Clinical Neuromuscular Disease 2001;2(4):179-83.
59. Schram G, Fournier A, Leduc H, Dahdah N, Therien J, Vanasse M, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. Journal of the American College of Cardiology 2013; Vol. 61, issue 9:948-54.
60. Siegel IM, Miller JE, Ray RD. Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study. Illinois Medical Journal 1974;145(1):32-3.
61. Silva EC, Machado DL, Resende MB, Silva RF, Zanoteli E, Reed UC. Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy. Arquivos de Neuro-psiquiatria 2012; Vol. 70, issue 3:191-5.
62. Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. American Journal of Cardiology 2003;91(6):769-72.
63. Simon VA, Resende MB, Simon MA, Zanoteli E, Reed UC. Duchenne muscular dystrophy: quality of life among 95 patients evaluated using the Life Satisfaction Index for Adolescents. Arquivos de Neuro-psiquiatria 2011; Vol. 69, issue 1:19-22.
64. Takeuchi F, Yonemoto N, Nakamura H, Shimizu R, Komaki H, Mori-Yoshimura M, et al. Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. Journal of Neurology 2013;260(12):3023-9.
65. Tunca O, Kabakus O, Herguner A, Karaduman A, Topaloglu H. Alternate day prednisone therapy in Duchenne muscular dystrophy. Neuromuscular Disorders 2001;11:630.
66. Vasanth A, Gourie-Devi M, Rajaram P, Taly AB, Venkataram BS, Ravishankar D, et al. Duchenne muscular dystrophy: therapeutic options and rehabilitation. European Journal of Neurology 1996;3(Suppl 2):20.
67. Wong BL, Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. Journal of Child Neurology 2002;17(3):183-9.
68. Yilmaz O, Karaduman A, Aras O, Basoglu B, Topaloğlu H. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Neuromuscular Disorders 2004; Vol. 14:581.
69. Yilmaz O, Karaduman A, Topaloğlu H. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. European Journal of Neurology 2004;11(8):541-4.
70. ACTRN12605000075684 . A randomized phase III study to evaluate the effectiveness of two different dosing regimens (high dose vs daily) of prednisone for boys with Duchenne muscular dystrophy in improving muscle strength and function and minimising side effects. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12605000075684 (accessed 26 April 2016).
71. CTRI/2009/091/000738 . A clinical trial to compare the two ways of giving steroids (daily versus intermittent) in ambulatory patients with Duchenne muscular dystrophy. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000605 accessed 28 April 2016.
72. Guglieri M, Van Ruiten HJA, Speed C, Hart K, Watson G, McColl E, et al. FOR-DMD: Double-blind randomised trial to optimise corticosteroid regime in Duchenne muscular dystrophy (DMD). Developmental Medicine and Child Neurology 2015; Vol. 57, issue Suppl s1:25-6.
73. NCT01603407 . Finding the optimum regimen for Duchenne muscular dystrophy (FOR-DMD). www.clinicaltrials.gov/ct2/show/NCT01603407 (accessed 14 December 2015).
74. Allsop KG, Ziter FA. Loss of strength and functional decline in Duchenne dystrophy. Archives of Neurology 1981;38(7):406-11.
75. Anderson JE, Weber M, Vargus C. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy. Cell Transplantation 2000;9(4):551-64.
76. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Annals of Neurology 1984;16(2):193-208.
77. Azarnoff DL. Steroid Therapy. 1st Edition. Philadelphia: Saunders, 1975.
78. Bal E, Sanwall W. A synergistic effect of glucocorticosteroids and insulin on the differentiation of myoblasts. Journal of Cell Physiology 1980;102:27-36.
79. Beenakker EAC, van der Hoeven JH, Fock JM, Maurits NM. Reference values of maximum isometric muscle force obtained in 270 children aged 4 -16 years by hand-held dynamometry. Neuromuscular Disorders 2001;11(5):441-6.
80. Beenakker EAC, Maurits NM, Fock JM, Brouwer OF, van der Hoeven JH. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. European Journal of Paediatric Neurology 2005;9(6):387-93.
81. Biggar WD, Bachrach LK, Henderson RC, Kalkwarf H, Plotkin H, Wong BL. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscular Disorders 2005;15(1):80-5.
82. Joint Formulary Committee. British National Formulary (online). www.medicinescomplete.com (accessed 4 April 2016).
83. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle & Nerve 1981;4(3):186-97.
84. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Province MA. Clinical investigation in Duchenne dystrophy. 2. Determination of the 'power' of therapeutic trials based on natural history. Muscle & Nerve 1983;6(2):91-103.
85. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscular Disorders 2003;13(2):166-72.
86. Bushby K, Muntoni F, Urtizberea, Hughes R, Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscular Disorders 2004;14(8-9):526-34.
87. K Bushby, R Griggs, MSG/ENMC for DMD Trial Study Group. 145th ENMC International Workshop: Planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD). 22-24th October 2006, Naarden, The Netherlands. Neuromuscular Disorders 2007;17(5):423-8.
88. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurology 2010;9(1):77-93.
89. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurology 2010;9(2):177-89.
90. Davis SE, Hynan LS, Limbers CA, Andersen CM, Greene MC, Varni JW, et al. The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales. Journal of Clinical Neuromuscular Disease 2010;11(3):97-109.
91. Deconinck N, Dan B. Pathophysiology of Duchenne muscular dystrophy: Current hypotheses. Pediatric Neurology 2007;36(1):1-7.
92. Dubowitz V. Muscle Disorders in Childhood. 2nd Edition. Philadelphia: Saunders, 1978.
93. Dubowitz V. Prednisone in Duchenne dystrophy. Neuromuscular Disorders 1991;1(3):161-3.
94. Dubowitz V. Muscle Disorders in Childhood. 2nd Edition. London: Saunders, 1995.
95. Dubowitz V. 75th European Neuromuscular Centre International workshop: 2nd workshop on the treatment of muscular dystrophy, 10-12 December, 1999, Naarden, The Netherlands. Neuromuscular Disorders 2000;10(4-5):313-20.
96. Dubowitz V. Prednisone for Duchenne muscular dystrophy. The Lancet Neurology 2005;4(5):264.
97. Dubrovsky AL, Angelini C, Bonifati DM, Pegoraro E, Mesa L. Steroids in muscular dystrophy: Where do we stand?. Neuromuscular Disorders 1998;8(6):380-4.
98. Dudley RWR, Danialou G, Govindaraju K, Lands L, Eidelman DE, Petrov BJ. Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stresses. American Journal of Pathology 2006;168(4):1276-87.
99. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscular Disorders 2002;12(10):926-9.
100. Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, et al. Managing Duchenne muscular dystrophy - the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscular Disorders 2007;17(6):470-5.
101. Elia M, Carter A, Bacon S, Winearls CG, Smith R. Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown. British Medical Journal (Clinical Research Ed) 1981;282(6261):351-4.
102. Emery AEH. Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscular Disorders 1991;1(1):19-29.
103. Emery AEH. Diagnostic Criteria for Neuromuscular Disorders. 2nd Edition. London: Royal Society of Medicine Press, 1997.
104. Emery AEH, Muntoni F. Duchenne muscular dystrophy. Oxford Monographs on Medical Genetics. 3rd Edition. Oxford: Oxford Medical Publications, 2003.
105. Engel AG, Biesecker G. Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Annals of Neurology 1982;12(3):289-96.
106. Frankel K, Rosser R. The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Human Pathology 1976;7(4):375-86.
107. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clinical Pharmacokinetics 1990;19(2):126-46.
108. Gardner-Medwin D. Clinical features and classification of the muscular dystrophies. British Medical Bulletin 1980;36(2):109-15.
109. Gloss D, Moxley RT III, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016;86:465-72.
110. Gomez-Merino E, Bach JR. Duchenne muscular dystrophy: prolongation of life by noninvasive ventilation and mechanically assisted coughing. American Journal of Physical and Medical Rehabilitation 2002;81(6):411-5.
111. Heckmatt JZ, Dubowitz V, Hyde SA, Florence J, Gabain AC, Thompson N. Prolongation of walking in Duchenne Muscular Dystrophy with lightweight orthoses; review of 57 cases. Developmental Medicine and Child Neurology 1985;27(2):149-54.
112. Heckmatt JZ, Rodillo E, Dubowitz V. Management of children: pharmacological and physical. British Medical Bulletin 1989;45(3):788-801.
113. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
114. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51(6):919-28.
115. Ishikawa Y, Bach JR, Ishikawa Y, Minami R. A management trial for Duchenne cardiomyopathy. American Journal of Physical Medicine and Rehabilitation 1995;74(5):345-50.
116. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. American Heart Journal 1999;137(5):895-902.
117. Jacobs SC, Bootsma AL, Willems PW, Bar PR, Wokke JH. Prednisolone can protect against exercise-induced muscle damage. Journal of Neurology 1996;243(5):410-6.
118. Jeppesen J, Green A, Steffensen BF, Rahbek J. The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscular Disorders 2003;13(10):804-12.
119. Kissel JT, Burrow K, Rammohan KW, Mendell JR. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group. Neurology 1991;41(5):667-72.
120. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. American Journal of Human Genetics 1989;45(4):498-506.
121. Matsumura K, Ohlendieck K, Ionasescu VV, Tome FM, Nonaka I, Burghes AH, et al. The role of the dystrophin-glycoprotein complex in the molecular pathogenesis of muscular dystrophies. Neuromuscular Disorders 1993;3(5):533-5.
122. Matsumura K, Campbell KP. Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Muscle & Nerve 1994;17(1):2-15.
123. Mendell JR, Sahenk Z, Prior TW. The childhood muscular dystrophies: diseases sharing a common pathogenesis of membrane instability. Journal of Child Neurology 1995;10(2):150-9.
124. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Annals of Neurology 2012;71(3):304-13.
125. Metzinger L, Passaquin AC, Leijendekker WJ, Poindron P, Ruegg UT. Modulation by prednisolone of calcium handling in skeletal muscle cells. British Journal of Pharmacology 1995;116(7):2811-6.
126. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097.
127. Morrow B, Zampoli M, van Aswegen H, Argent A. Mechanical insufflation-exsufflation for people with neuromuscular disorders. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD010044.pub2]
128. Moxley RT 3rd, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, et al. Practice Parameter: corticosteroid treatment of Duchenne dystrophy, report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64(1):13-20.
129. Medical Research Council. Aids to the Investigation of Peripheral Nerve Injuries. London: HMSO, 1976.
130. Muntoni F, Fisher I, Morgan JE, Abraham D. Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research. Neuromuscular Disorders 2002;12(Suppl 1):S162-5.
131. Muntoni F. Cardiomyopathy in muscular dystrophies. Current Opinion in Neurology 2003;16(5):577-83.
132. Muntoni F, Bushby K, Manzur AY. Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy 24 January 2005, London, UK. Neuromuscular Disorders 2006;16(3):210-9.
133. Noguchi S, Tsukahara T, Fujita M, Kurokawa R, Tachikawa M, Toda T, et al. cDNA microarray analysis of individual Duchenne muscular dystrophy patients. Human Molecular Genetics 2003;12(6):595-600.
134. Pasquini F, Guerin C, Blake D, Davies K, Karpati G, Holland P. The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells. Neuromuscular Disorders 1995;5(2):105-14.
135. Passaquin AC, Lhote P, Ruegg UT. Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. British Journal of Pharmacology 1998;124(8):1751-9.
136. Pescatori M, Broccolini A, Minetti C, Bertini E, Bruno C, D'amico A. Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. The FASEB Journal 2007;21(4):1210-26.
137. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proceedings of the National Academy of Sciences, USA 1993;90(8):3710-4.
138. Petrof BJ. The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. Molecular Cell Biochemistry 1998;179(1-2):111-23. [MEDLINE: 98202355]
139. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Human Molecular Genetics 2002;11(3):263-72.
140. Porter JD, Merriam AP, Leahy P, Gong B, Khanna S. Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Human Molecular Genetics 2003;12(15):1813-21.
141. Quinlivan R, Roper H, Davie M, Shaw NJ, McDonagh J, Bushby K. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscular Disorders 2005;15(1):72-9.
142. Quinlivan R, Bourke JP, Bueser T. Prevention and treatment for cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD009068.pub2]
143. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
144. Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, et al. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. Journal of Neurology, Neurosurgery, & Psychiatry 2016;87(2):149-55.
145. Rifai Z, Welle E, Moxley RT 3rd, Lorenson M, Griggs RC. Effect of prednisone on protein metabolism in Duchenne muscular dystrophy. American Journal of Physiology 1995;268(1 pt 1):E67-E74.
146. Rodillo EB, Fernandez-Bermejo E, Heckmatt JZ, Dubowitz V. Prevention of rapidly progressive scoliosis in Duchenne muscular dystrophy by prolongation of walking with orthoses. Journal of Child Neurology 1988;3(4):269-74.
147. Scott OM, Hyde SA, Goddard C, Dubowitz V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle & Nerve 1982;5(4):291-301.
148. Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, et al. North Star Clinical Network for Paediatric Neuromuscular Disease. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiotherapy Research International 2012;17(2):101-9.
149. Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 1993;43(3):527-32.
150. Spencer GE, Vignos PJ. Bracing for ambulation in childhood progressive muscular dystrophy. Journal of Bone and Joint Surgery 1962;44A:234-42.
151. Vandebrouck C, Imbert N, Dupont G, Cognard C, Raymond G. The effect of methylprednisone on intracellular calcium of normal and dystrophic human skeletal muscle cells. Neuroscience Letters 1999;269(2):110-4.
152. Manzur AY, Pike M, Elliot T. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003725.pub2]
153. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD003725.pub2]
154. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD003725.pub2]